An UpToDate review on "Screening for prostate cancer" (Hoffman, 2018) recommend prostate cancer screening beginning at age 40 to 45 years for men at high risk (e.g., black men, men with family history of prostate cancer, particularly in relatives younger than age 65, and men who are know...
Screening for prostate cancer has generated considerable debate within the medical and broader community, as demonstrated by the varying recommendations made by medical organizations and governed by national policies. To better inform individual patient decision-making and health policy decisions, we need ...
Prostate cancer screening has historically been a controversial subject, with concerns raised both aroundfalse positivesleading to unnecessary invasive treatments and false negatives leading to cancers being missed. This is gradually changing due to MRI scans which can avoid unnecessary biopsies and the us...
At present, there is no national NHS screening programme for prostate cancer. Most men with early prostate cancer won’t experience any signs or symptoms either, so it's important to understand your risk and know what the warning signs are. This guide looks at what prostate cancer is, the ...
Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA an...
This cluster randomized trial evaluates the effect of a single prostate-specific antigen (PSA) screening test on 10-year prostate cancer–specific
Prostate cancer screening for older men 'unlikely' - Health News - NHS Choices Information on conditions and treatments from the world's largest medical library. Find out what works. N Choices - Department of Health 被引量: 0发表: 0年 Why is prostate cancer screening so common when the ...
Multiparametric MRI of the prostate is now recommended as the initial diagnostic test for men presenting with suspected prostate cancer, with a negative MRI enabling safe avoidance of biopsy and a positive result enabling MRI-directed sampling of lesions. The diagnostic pathway consists of several step...
Targeting tests for prostate cancer at the men most likely to develop the disease could halve the number needed to be screened, reduce overdiagnosis, and potentially save the NHS millions of pounds, suggests research. With funding from Cancer Research UK, researchers from London and Cambridge ...
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 2011;107(1):28–39. doi:10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14. Blueggel M, Chamrad D, Meyer ...